JP2018035142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018035142A5 JP2018035142A5 JP2017154022A JP2017154022A JP2018035142A5 JP 2018035142 A5 JP2018035142 A5 JP 2018035142A5 JP 2017154022 A JP2017154022 A JP 2017154022A JP 2017154022 A JP2017154022 A JP 2017154022A JP 2018035142 A5 JP2018035142 A5 JP 2018035142A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- cycloalkyl
- heteroatom group
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005842 heteroatom Chemical group 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 108091033409 CRISPR Proteins 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000004419 alkynylene group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000003536 tetrazoles Chemical class 0.000 claims 4
- 150000003852 triazoles Chemical class 0.000 claims 4
- 125000006743 (C1-C60) alkyl group Chemical group 0.000 claims 2
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims 2
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 2
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000211P | 2014-05-19 | 2014-05-19 | |
| US62/000,211 | 2014-05-19 | ||
| US201462001540P | 2014-05-21 | 2014-05-21 | |
| US62/001,540 | 2014-05-21 | ||
| US201562139254P | 2015-03-27 | 2015-03-27 | |
| US62/139,254 | 2015-03-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567971A Division JP6193513B2 (ja) | 2014-05-19 | 2015-05-05 | Ａｓｇｐｒ標的化剤としての置換６，８−ジオキサビシクロ［３．２．１］オクタン−２，３−ジオール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018035142A JP2018035142A (ja) | 2018-03-08 |
| JP2018035142A5 true JP2018035142A5 (enExample) | 2018-10-04 |
| JP6663889B2 JP6663889B2 (ja) | 2020-03-13 |
Family
ID=53200246
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567971A Active JP6193513B2 (ja) | 2014-05-19 | 2015-05-05 | Ａｓｇｐｒ標的化剤としての置換６，８−ジオキサビシクロ［３．２．１］オクタン−２，３−ジオール化合物 |
| JP2017154022A Active JP6663889B2 (ja) | 2014-05-19 | 2017-08-09 | Ａｓｇｐｒ標的化剤としての置換６，８−ジオキサビシクロ［３．２．１］オクタン−２，３−ジオール化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567971A Active JP6193513B2 (ja) | 2014-05-19 | 2015-05-05 | Ａｓｇｐｒ標的化剤としての置換６，８−ジオキサビシクロ［３．２．１］オクタン−２，３−ジオール化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US9340553B2 (enExample) |
| EP (1) | EP3145934B1 (enExample) |
| JP (2) | JP6193513B2 (enExample) |
| KR (1) | KR102149572B1 (enExample) |
| CN (1) | CN106459120A (enExample) |
| AU (1) | AU2015262993B2 (enExample) |
| BR (1) | BR112016026809A2 (enExample) |
| CA (1) | CA2891717C (enExample) |
| DK (1) | DK3145934T5 (enExample) |
| ES (1) | ES2841400T3 (enExample) |
| HU (1) | HUE052146T2 (enExample) |
| IL (1) | IL248667B (enExample) |
| MX (1) | MX381383B (enExample) |
| MY (1) | MY181586A (enExample) |
| NZ (1) | NZ725600A (enExample) |
| PE (1) | PE20170024A1 (enExample) |
| PH (1) | PH12016502304A1 (enExample) |
| PL (1) | PL3145934T3 (enExample) |
| PT (1) | PT3145934T (enExample) |
| RU (1) | RU2696490C2 (enExample) |
| SA (1) | SA516380328B1 (enExample) |
| SG (1) | SG11201608936UA (enExample) |
| SI (1) | SI3145934T1 (enExample) |
| TW (1) | TWI579286B (enExample) |
| UY (1) | UY36126A (enExample) |
| WO (1) | WO2015177668A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US12533312B2 (en) | 2011-02-04 | 2026-01-27 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
| US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| BR112016026809A2 (pt) | 2014-05-19 | 2017-12-12 | Pfizer | compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr |
| WO2017083368A1 (en) * | 2015-11-12 | 2017-05-18 | Pfizer Inc. | Tissue-specific genome engineering using crispr-cas9 |
| US12239706B2 (en) | 2015-11-30 | 2025-03-04 | Seed Health, Inc. | Method and system for protecting monarch butterflies from pesticides |
| CA3134765A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
| US20230097887A1 (en) | 2018-04-09 | 2023-03-30 | Yale University | Bi-functional Molecules to Degrade Circulating Proteins |
| US12364766B2 (en) | 2018-04-09 | 2025-07-22 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| US12485178B2 (en) | 2018-04-09 | 2025-12-02 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| WO2020055547A2 (en) | 2018-08-18 | 2020-03-19 | Seed Health, Inc. | Methods and compositions for honey bee health |
| CN109232690A (zh) * | 2018-09-10 | 2019-01-18 | 南方医科大学南方医院 | 一种正电子显像剂标准品前体及其制备方法 |
| RU2712497C1 (ru) * | 2018-11-26 | 2020-01-29 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания ДНК на основе Cas9 белка из биотехнологически значимой бактерии Clostridium cellulolyticum |
| CN113301925A (zh) | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
| BR112022014522A2 (pt) | 2020-01-31 | 2022-09-20 | Avilar Therapeutics Inc | Compostos degradadores, composição farmacêutica, métodos para tratar transtornos, compostos |
| BR112022023465A2 (pt) | 2020-05-22 | 2023-01-10 | Wave Life Sciences Ltd | Agente de rnai de fita dupla (dsrnai), composição de oligonucleotídeo quiralmente controlada, oligonucleotídeo de fita dupla, método para reduzir o nível e/ou a atividade de um transcrito ou uma proteína codificada pelo mesmo, e método para supressão específica quanto ao alelo de um transcrito de uma sequência de ácidos nucleicos |
| US20240309084A1 (en) | 2021-01-19 | 2024-09-19 | Novartis Ag | Degradation of extracellular targets |
| WO2022170216A2 (en) * | 2021-02-08 | 2022-08-11 | Emendobio Inc. | Omni 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 crispr nucleases |
| IL305665A (en) * | 2021-03-10 | 2023-11-01 | Biohaven Therapeutics Ltd | Bifunctional degraders of galactose-deficient immunoglobulins |
| KR20240017423A (ko) | 2021-05-03 | 2024-02-07 | 아빌라 테라퓨틱스, 인크. | 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물 |
| WO2023288033A1 (en) | 2021-07-14 | 2023-01-19 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| WO2023009554A1 (en) * | 2021-07-26 | 2023-02-02 | Avilar Therapeutics, Inc. | Methods to reduce adverse effects of gene or biologics therapy |
| EP4392430A1 (en) * | 2021-08-27 | 2024-07-03 | Yale University | Molecular degraders of extracellular proteins |
| WO2024167900A2 (en) * | 2023-02-06 | 2024-08-15 | Biohaven Therapeutics Ltd. | Bifunctional molecules to target degradation of tumor necrosis factor |
| WO2024229005A2 (en) * | 2023-04-30 | 2024-11-07 | Biohaven Therapeutics Ltd. | Asgpr binders and compositions and methods thereof |
| GB202311324D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| US20250051771A1 (en) | 2023-07-24 | 2025-02-13 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| GB202311334D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| WO2025157263A1 (zh) * | 2024-01-26 | 2025-07-31 | 浙江养生堂天然药物研究所有限公司 | 偶联物及其制备方法和用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58121243A (ja) * | 1982-01-12 | 1983-07-19 | Sumitomo Chem Co Ltd | 新規ビシクロオクタン誘導体及びその製造法 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5104797A (en) | 1988-05-05 | 1992-04-14 | The Procter & Gamble Company | Process for preparing 5-c-hydroxymethyl aldohexose-based compounds |
| US5064672A (en) * | 1988-05-05 | 1991-11-12 | The Procter & Gamble Company | Functional sugar substitutes with reduced calories |
| US5041541A (en) * | 1988-05-05 | 1991-08-20 | The Procter & Gamble Company | Functional sugar substituted with reduced calories |
| WO1991009537A1 (en) | 1989-12-21 | 1991-07-11 | The Procter & Gamble Company | Food compositions containing reduced calorie fats and reduced calorie sugars |
| EP0607245B1 (en) | 1991-10-04 | 1998-04-22 | The Procter & Gamble Company | Cholesterol lowering compounds and process for making them |
| JPH09506594A (ja) * | 1993-12-07 | 1997-06-30 | ネオルクス コーポレーション | プレターゲティング方法及び化合物 |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| EP1783137A4 (en) * | 2004-08-26 | 2014-10-22 | Nippon Shinyaku Co Ltd | GALACTOSIS DERIVATIVE, DRUG VECTOR AND THERAPEUTIC PREPARATION |
| US20080312167A1 (en) | 2005-05-10 | 2008-12-18 | Sulejman Alihodzic | 4'' Amino Linked Macrolides Useful for the Treatment of Microbial Infections |
| WO2007056389A2 (en) | 2005-11-07 | 2007-05-18 | University Of South Carolina | Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| PE20110288A1 (es) * | 2008-08-28 | 2011-05-26 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| HRP20150107T1 (xx) | 2009-11-02 | 2015-03-13 | Pfizer Inc. | Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola |
| CN102372722A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
| WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
| AR086922A1 (es) | 2011-06-13 | 2014-01-29 | Panacea Biotec Ltd | Derivados de 3,4,5-trihidroxi-6-(hidroximetil)tetrahidro-2h-pirano utiles para el tratamiento de diabetes y dislipidemias, composiciones farmaceuticas que los contienen y metodo para prepararlos |
| EP2755722B1 (en) | 2011-09-13 | 2017-05-24 | Panacea Biotec Ltd. | Novel sglt inhibitors |
| EP4570908A3 (en) | 2012-05-25 | 2025-10-22 | The Regents of the University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| CN103570657A (zh) | 2012-07-19 | 2014-02-12 | 天津药物研究院 | 一类含偕二甲基的苯基c-葡萄糖苷衍生物、其制备方法和用途 |
| WO2014018671A1 (en) * | 2012-07-24 | 2014-01-30 | Regents Of The University Of Minnesota | Therapeutic compounds for the treatment of cancer |
| AR092924A1 (es) | 2012-10-09 | 2015-05-06 | Sanofi Sa | Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| CN103772449B (zh) | 2012-10-26 | 2017-12-26 | 上海阳帆医药科技有限公司 | C‑芳基葡萄糖苷衍生物及其制备方法与用途 |
| WO2014093595A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| CN103864737B (zh) | 2012-12-17 | 2016-08-17 | 天津药物研究院 | 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途 |
| WO2014094544A1 (zh) | 2012-12-17 | 2014-06-26 | 天津药物研究院 | 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途 |
| WO2014159151A1 (en) | 2013-03-14 | 2014-10-02 | Msd International Gmbh | Methods for preparing sglt2 inhibitors |
| PT2981269T (pt) | 2013-04-04 | 2023-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
| BR112016026809A2 (pt) * | 2014-05-19 | 2017-12-12 | Pfizer | compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr |
| CN104031098A (zh) | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
| CN104017031A (zh) | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
-
2015
- 2015-05-05 BR BR112016026809A patent/BR112016026809A2/pt not_active Application Discontinuation
- 2015-05-05 SG SG11201608936UA patent/SG11201608936UA/en unknown
- 2015-05-05 NZ NZ725600A patent/NZ725600A/en unknown
- 2015-05-05 CN CN201580028359.2A patent/CN106459120A/zh active Pending
- 2015-05-05 MY MYPI2016704172A patent/MY181586A/en unknown
- 2015-05-05 HU HUE15724064A patent/HUE052146T2/hu unknown
- 2015-05-05 MX MX2016015199A patent/MX381383B/es unknown
- 2015-05-05 AU AU2015262993A patent/AU2015262993B2/en active Active
- 2015-05-05 ES ES15724064T patent/ES2841400T3/es active Active
- 2015-05-05 KR KR1020167035265A patent/KR102149572B1/ko active Active
- 2015-05-05 JP JP2016567971A patent/JP6193513B2/ja active Active
- 2015-05-05 PT PT157240649T patent/PT3145934T/pt unknown
- 2015-05-05 DK DK15724064.9T patent/DK3145934T5/da active
- 2015-05-05 WO PCT/IB2015/053282 patent/WO2015177668A1/en not_active Ceased
- 2015-05-05 SI SI201531464T patent/SI3145934T1/sl unknown
- 2015-05-05 PE PE2016002255A patent/PE20170024A1/es unknown
- 2015-05-05 RU RU2016142704A patent/RU2696490C2/ru active
- 2015-05-05 EP EP15724064.9A patent/EP3145934B1/en active Active
- 2015-05-05 PL PL15724064T patent/PL3145934T3/pl unknown
- 2015-05-15 CA CA2891717A patent/CA2891717C/en active Active
- 2015-05-15 UY UY0001036126A patent/UY36126A/es not_active Application Discontinuation
- 2015-05-15 TW TW104115586A patent/TWI579286B/zh active
- 2015-05-18 US US14/714,484 patent/US9340553B2/en active Active
-
2016
- 2016-04-07 US US15/093,178 patent/US9617293B2/en active Active
- 2016-11-01 IL IL248667A patent/IL248667B/en active IP Right Grant
- 2016-11-17 SA SA516380328A patent/SA516380328B1/ar unknown
- 2016-11-18 PH PH12016502304A patent/PH12016502304A1/en unknown
-
2017
- 2017-02-16 US US15/434,508 patent/US10039778B2/en active Active
- 2017-08-09 JP JP2017154022A patent/JP6663889B2/ja active Active
-
2018
- 2018-06-29 US US16/023,232 patent/US10376531B2/en active Active
-
2019
- 2019-06-24 US US16/450,649 patent/US10813942B2/en active Active